Artios announces £110m Series C financing

Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, has announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.